Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients

Recurrent Mantle Cell Lymphoma Clinical Trial

— MendCART  

Official title:

A Phase I Study of Anti-CD22:TCRz:4-1BB T-cells in Patient With CD22-Positive Recurrent Lymphoma That is Resistant or Refractory to Prior Anti-CD22:TCRz:CD28 Immunotherapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02721407
• Other study ID #: CD22CART
• Status: Recruiting
• Phase: Phase 1
• First received: March 23, 2016
• Last updated: March 8, 2017
• Start date: March 2016
• Est. completion date: December 2019

Study information

• Verified date: March 2017
• Source: Xinqiao Hospital of Chongqing
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to study the feasibility and efficacy of anti-CD22:TCRz:4-1BB chimeric antigen receptor (CAR)-modified T (CAR-T) cells in treating recurrent patients with refractory or resistant lymphoma to anti-CD19:TCRz:CD28 CAR-T cells. Recently, cancer immunotherapy, treatments aiming to arm patients with immunity specifically against cancer cells, has emerged as a promising therapeutic strategy. Among the many emerging immunotherapeutic approaches, clinical trials utilizing CARs against B cell malignancies have demonstrated remarkable potential. CARs combine the variable region of an antibody with T-cell signaling moieties to confer T-cell activation with the targeting specificity of an antibody. Thus, CARs are not MHC-restricted so they are not vulnerable to MHC down regulation by tumors. However, defined by the recession of evaluable lesions, the persistence and efficacy of CAR-T cells are still restricted by the "target" selection. Previous clinical studies largely utilized CD19 for the in vivo targeting of CAR-T cells, which preferentially become refractory or resistant due to the heterogeneity of lymphoma. This clinical investigation is to test a hypothesis whether anti-CD22 CAR-T cells work more effective in lymphoma patients refractory or resistent to anti-CD19:TCRz:CD28 CAR-T cells.

Description:

Primary Objectives

1. To determine the safety of CD22.CAR-T cells in lymphoma patients refractory or resistent to anti-CD19:TCRz:CD28 CAR-T cells

2. To determine in vivo dynamics and persistency of CD22.CAR-T cells.

Secondary Objectives

1. To determine the feasibility of CD22.CAR-T cells in lymphoma patients refractory or resistent to anti-CD19:TCRz:CD28 CAR-T cells

2. To determine in vivo dynamics and persistency of CD22.CAR-T cells.

3. To assess the intratumoral infiltration of CD22.CAR-T cells.

4. To correlate the subsets and differentiation of CD22.CAR-T cells to observed anti-tumor efficacy

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 2019
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1.18 Years to 70 Years, Male and female;

2.Expected survival > 12 weeks;

3.Performance score 0-2;

4.Histologically confirmed as CD19-positive lymphoma and who meet one of the following conditions;

• Patient receive at least 2-4 prior combination chemotherapy regimens (not including single agent monoclonal antibody therapy) and fail to achieve CR; or have disease recurrence; or not eligible for allogeneic stem cell transplantation; or disease responding or stable after most recent therapy but refused further treatment;

• Disease recurrence after stem cell transplantation;

• Diagnosis as lymphoma, but refuse conventional treatment such as chemotherapy, radiation, stem cell transplantation and monoclonal antibody therapy

5.Creatinine < 2.5 mg/dl;

6.ALT/AST < 3x normal;

7.Bilirubin < 2.0 mg/dl;

8.Adequate venous access for apheresis, and no other contraindications for leukapheresis;

9.Take contraceptive measures before recruit to this trial;

10.Written voluntary informed consent is given.

11.Refractory ot resistant to prior anti-CD19 CAR-Ts

12.At least one evaluable CD22-positive recurrent lesion, confirmed by two independent pathologist.

Exclusion Criteria:

1. Patients with symptoms of central nervous system

2. Accompanied by other malignant tumor

3. Active hepatitis B or C, HIV infection

4. Any other diseases could affect the outcome of this trial

5. Suffering severe cardiovascular or respiratory disease

6. Poorly controlled hypertension

7. A history of mental illness and poorly controlled

8. Taking immunosuppressive agents within 1 week due to organ transplantation or other disease which need long-lasting administration

9. Occurrence of unstable pulmonary embolism, deep vein thrombosis, or other major arterial/venous thromboembolic events 30 days prior to assignment

10. Reaching a steady dose if receiving anticoagulant therapy before assignment

11. Female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion

12. Pregnant or lactating women

13. Subject suffering disease affects the understanding of informed consent or comply with study protocol.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Follicular
• Lymphoma, Large B-Cell, Diffuse
• Lymphoma, Mantle-Cell
• Lymphoma, Non-Hodgkin
• Recurrent Adult Diffuse Large Cell Lymphoma
• Recurrent Follicular Lymphoma
• Recurrent Mantle Cell Lymphoma
• Stage III/IV Adult Diffuse Large Cell Lymphoma
• Stage III/IV Follicular Lymphoma
• Stage III/IV Mantle Cell Lymphoma

Intervention

Drug:
• Retroviral vector-transduced autologous T cells to express CD22-specific CARs

Locations

Country	Name	City	State
China	Department of Oncology, Xinqiao Hospital	ChongQing	Chongqing

Sponsors (2)

Lead Sponsor	Collaborator
Xinqiao Hospital of Chongqing	Xuzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0		4 Weeks
Secondary	Overall complete remission rate defined by the standard response criteria for malignant lymphoma for each arm		8 Weeks
Secondary	Duration of CAR-positive T cells in circulation		6 months
Secondary	Total number of CAR-positive T cells infiltrated into lymphoma tissue		6 months